Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2017

27.03.2017 | Epidemiology

Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer

verfasst von: Yaeji Lim, Eun Sook Ko, Boo-Kyung Han, Eun Young Ko, Ji Soo Choi, Jeong Eon Lee, Se Kyung Lee

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether BPE in preoperative breast MRI influences patients’ recurrence-free survival (RFS).

Methods

Between February 2010 and December 2011, 804 consecutive women with invasive breast cancer who had undergone preoperative breast MRI and curative cancer surgery were identified. BPE was visually graded by two reviewers. We determined the correlation between BPE grade and other clinicopathological variables, including age, adjuvant therapy, menopausal status, histologic grade, T stage, N stage, lymphovascular invasion, molecular subtype, surgical margin status, and mammographic density. A Cox proportional hazards model was used to analyze the effects of clinicopathological variables and radiological findings (BPE grade, mammographic density) on RFS.

Results

High BPE was associated with premenopausal status (Ps < 0.0001), higher mammographic density (Ps < 0.0001), progesterone receptor positivity (Ps = 0.039, 0.007, respectively), presence of lymphovascular invasion (Ps = 0.008, 0.001, respectively), and close surgical margin (Ps < 0.0001). Recurrences were observed in 75 patients after a mean follow-up period of 61.8 months (range 4–81 months). Non-minimal BPE grade (RFS hazard ratio = 3.086, P = 0.003 for reader 1; RFS hazard ratio = 2.221, P = 0.075 for reader 2) and T3 stage were associated with worse outcomes in postmenopausal women. In premenopausal women, non-minimal BPE grade by readers 1 and 2 did not affect the patients’ outcomes.

Conclusions

Increased BPE on preoperative breast MRI in postmenopausal women has potential as a predictor of poor RFS.
Literatur
1.
Zurück zum Zitat Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen C (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203(1):145–149CrossRefPubMed Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, Claussen C (1997) Menstrual cycle and age: influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology 203(1):145–149CrossRefPubMed
2.
Zurück zum Zitat Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lultterbey G et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical phase dependency. Radiology 203(1):137–144CrossRefPubMed Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lultterbey G et al (1997) Healthy premenopausal breast parenchyma in dynamic contrast enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical phase dependency. Radiology 203(1):137–144CrossRefPubMed
3.
Zurück zum Zitat Reichenbach JR, Przetak C, Klinger G, Kaiser WA (1999) Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 23(3):407–413CrossRefPubMed Reichenbach JR, Przetak C, Klinger G, Kaiser WA (1999) Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. J Comput Assist Tomogr 23(3):407–413CrossRefPubMed
4.
Zurück zum Zitat Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235(1):36–41CrossRefPubMed Delille JP, Slanetz PJ, Yeh ED, Halpern EF, Garrido L (2005) Hormone replacement therapy in postmenopausal women: breast tissue perfusion determined with MR imaging—initial observations. Radiology 235(1):36–41CrossRefPubMed
5.
Zurück zum Zitat Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M et al (1991) Mammographic densities and risk of breast cancer. Cancer 67(11):2833–2838CrossRefPubMed Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M et al (1991) Mammographic densities and risk of breast cancer. Cancer 67(11):2833–2838CrossRefPubMed
6.
Zurück zum Zitat Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675CrossRefPubMed Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB et al (1995) Quantitative classification of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst 87(9):670–675CrossRefPubMed
7.
Zurück zum Zitat Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR 196(1):218–224CrossRefPubMed Hambly NM, Liberman L, Dershaw DD, Brennan S, Morris EA (2011) Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up. AJR 196(1):218–224CrossRefPubMed
8.
Zurück zum Zitat DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD (2012) Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR 198(4):W373–W380CrossRefPubMed DeMartini WB, Liu F, Peacock S, Eby PR, Gutierrez RL, Lehman CD (2012) Background parenchymal enhancement on breast MRI: impact on diagnostic performance. AJR 198(4):W373–W380CrossRefPubMed
9.
Zurück zum Zitat King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260(1):50–60CrossRefPubMed King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA (2011) Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology 260(1):50–60CrossRefPubMed
10.
Zurück zum Zitat Uematsu T, Kasami M, Watanabe J (2011) Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol 21(11):2261–2267CrossRefPubMed Uematsu T, Kasami M, Watanabe J (2011) Does the degree of background enhancement in breast MRI affect the detection and staging of breast cancer? Eur Radiol 21(11):2261–2267CrossRefPubMed
11.
Zurück zum Zitat Choi JS, Ko ES, Ko EY, Han BK, Nam SJ (2016) Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 95(9):e3000CrossRef Choi JS, Ko ES, Ko EY, Han BK, Nam SJ (2016) Background parenchymal enhancement on preoperative magnetic resonance imaging: association with recurrence-free survival in breast cancer patients treated with neoadjuvant chemotherapy. Medicine (Baltimore) 95(9):e3000CrossRef
12.
Zurück zum Zitat Morris EA, Comstock CE, Lee CH, et al. (2013) ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, breast imaging reporting and data system. American College of Radiology, Reston. Morris EA, Comstock CE, Lee CH, et al. (2013) ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, breast imaging reporting and data system. American College of Radiology, Reston.
13.
Zurück zum Zitat Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J (2013) Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 138(1):119–126CrossRefPubMed Youk JH, Gweon HM, Son EJ, Kim JA, Jeong J (2013) Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemical profile. Breast Cancer Res Treat 138(1):119–126CrossRefPubMed
14.
Zurück zum Zitat Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174CrossRefPubMed Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33(1):159–174CrossRefPubMed
15.
Zurück zum Zitat Söderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L (1997) Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176(1 Pt 1):123–128CrossRefPubMed Söderqvist G, Isaksson E, von Schoultz B, Carlstrom K, Tani E, Skoog L (1997) Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol 176(1 Pt 1):123–128CrossRefPubMed
16.
Zurück zum Zitat Ko ES, Lee BH, Choi HY, Kim RB, Noh WC (2011) Background enhancement in breast MR: correlation with breast density in mammography and background echotexture in ultrasound. Eur J Radiol 80(3):719–723CrossRefPubMed Ko ES, Lee BH, Choi HY, Kim RB, Noh WC (2011) Background enhancement in breast MR: correlation with breast density in mammography and background echotexture in ultrasound. Eur J Radiol 80(3):719–723CrossRefPubMed
17.
Zurück zum Zitat Cubuk R, Tasali N, Narin B, Keskiner F, Celik L, Guney S (2010) Correlation between breast density in mammography and background enhancement in MR mammography. Radiol Med (Torino) 115(3):434–441CrossRef Cubuk R, Tasali N, Narin B, Keskiner F, Celik L, Guney S (2010) Correlation between breast density in mammography and background enhancement in MR mammography. Radiol Med (Torino) 115(3):434–441CrossRef
18.
Zurück zum Zitat Sogani J, Morris EA, Kaplan JB, D’Alessio D, Goldman D, Moskowitz CS et al (2017) Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging. Radiology 282(1):63–73CrossRefPubMed Sogani J, Morris EA, Kaplan JB, D’Alessio D, Goldman D, Moskowitz CS et al (2017) Comparison of background parenchymal enhancement at contrast-enhanced spectral mammography and breast MR imaging. Radiology 282(1):63–73CrossRefPubMed
19.
Zurück zum Zitat Folkman J (1995) Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333(26):1757–1763CrossRefPubMed Folkman J (1995) Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333(26):1757–1763CrossRefPubMed
20.
Zurück zum Zitat Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26(11):2350–2357CrossRefPubMed Bhatelia K, Singh K, Singh R (2014) TLRs: linking inflammation and breast cancer. Cell Signal 26(11):2350–2357CrossRefPubMed
21.
Zurück zum Zitat Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276(2):371–380CrossRefPubMedPubMedCentral Dontchos BN, Rahbar H, Partridge SC et al (2015) Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology 276(2):371–380CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27–36CrossRefPubMed Anderson WF, Chatterjee N, Ershler WB, Brawley OW (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27–36CrossRefPubMed
23.
Zurück zum Zitat Horwitz KB, McGuire WL (1978) Estrogen control progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J Biol Chem 253(7):2223–2228PubMed Horwitz KB, McGuire WL (1978) Estrogen control progesterone receptor in human breast cancer: correlation with nuclear processing of estrogen receptor. J Biol Chem 253(7):2223–2228PubMed
24.
Zurück zum Zitat Purdie CA, Quinlan P, Jordan LB et al (2014) Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 110(3):565–572CrossRefPubMed Purdie CA, Quinlan P, Jordan LB et al (2014) Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study. Br J Cancer 110(3):565–572CrossRefPubMed
25.
Zurück zum Zitat Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059–1065CrossRefPubMed Dowsett M, Allred C, Knox J et al (2008) Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26(7):1059–1065CrossRefPubMed
26.
Zurück zum Zitat Chatterton RT Jr, Lydon JP, Mehta RG et al (2002) Role of progesterone receptor (PR) in susceptibility of mouse mammary gland to 7, 12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188(1–2):47–52CrossRefPubMed Chatterton RT Jr, Lydon JP, Mehta RG et al (2002) Role of progesterone receptor (PR) in susceptibility of mouse mammary gland to 7, 12-dimethylbenz[a]anthracene-induced hormone-independent preneoplastic lesions in vitro. Cancer Lett 188(1–2):47–52CrossRefPubMed
27.
Zurück zum Zitat Conneely OM, Jericevic BM, Lydon JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8(2):205–214CrossRefPubMed Conneely OM, Jericevic BM, Lydon JP (2003) Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 8(2):205–214CrossRefPubMed
28.
Zurück zum Zitat Kougioumtzi A, Tsaparas P, Magklara A (2014) Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS ONE 9(6):e98404CrossRefPubMedPubMedCentral Kougioumtzi A, Tsaparas P, Magklara A (2014) Deep sequencing reveals new aspects of progesterone receptor signaling in breast cancer cells. PLoS ONE 9(6):e98404CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Scaranelo AM, Carrillo MC, Fleming R, Jacks LM, Kulkarni SR, Crystal P (2013) Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density. Radiology 267(3):692–700CrossRefPubMed Scaranelo AM, Carrillo MC, Fleming R, Jacks LM, Kulkarni SR, Crystal P (2013) Pilot study of quantitative analysis of background enhancement on breast MR images: association with menstrual cycle and mammographic breast density. Radiology 267(3):692–700CrossRefPubMed
30.
Zurück zum Zitat Melsaether A, McDermott M, Gupta D, Pysarenko K, Shaylor SD, Moy L (2014) Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training. AJR 203(1):209–215CrossRefPubMed Melsaether A, McDermott M, Gupta D, Pysarenko K, Shaylor SD, Moy L (2014) Inter- and intrareader agreement for categorization of background parenchymal enhancement at baseline and after training. AJR 203(1):209–215CrossRefPubMed
31.
Zurück zum Zitat Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746CrossRefPubMed Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746CrossRefPubMed
Metadaten
Titel
Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer
verfasst von
Yaeji Lim
Eun Sook Ko
Boo-Kyung Han
Eun Young Ko
Ji Soo Choi
Jeong Eon Lee
Se Kyung Lee
Publikationsdatum
27.03.2017
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2017
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4217-5

Weitere Artikel der Ausgabe 3/2017

Breast Cancer Research and Treatment 3/2017 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.